Nicandro JP, Tennis P, Bennett L, Hollis K, Shin P, Chuang E, Andrews E. Disability or restriction of daily activities is the most common indicator of disease severity in female patients with severe IBS-D: an analysis of the alosetron patient survey. Poster presented at the 2010 American College of Gastroenterology (ACG) Annual Scientific Meeting; October 2010. San Antonio, TX. [abstract] Am J Gastroenterol. 2010 Oct; 105(Suppl. 1):S410.
Hollis KA, Tennis P, Nicandro J, Chuang E, Sweeney CT, Bennett L, Andrews E. Temporal trends in compliance with the alosetron risk management program. Poster presented at the 26th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2010. Brighton, United Kingdom.
Hollis KA, Calingaert B, Price M, Andrews E, Moy L, Kooijmans M, Cristiano L, Bozic C. Tysabri TOUCH prescriber program risk management program (RiskMAP) surveys. Poster presented at the 26th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2010. Brighton, United Kingdom.
Nicandro J, Tennis P, Shin P, Hickman P, Bennett L, Hollis KA, Andrews E. One-year treatment continuation with alosetron is high irrespective of ibs-d severity criteria. Poster presented at the 2010 Digestive Disease Week; April 30, 2010.
Cook SF, Lanza L, Zhou X, Sweeney CT, Goss D, Hollis K, Mangel AW, Fehnel SE. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther. 2008 Jun 15;27(12):1224-32.
Cook SF, Bell T, Sweeney CT, Fehnel SE, Hollis KA. Impact on quality of life of constipation associated gi symptoms related to opioid treatment in chronic pain patients: pAC-QoL results from the opioid survey. Poster presented at the 26th Annual Scientific Meeting of the American Pain Society; May 2007.
Tennis P, Andrews E, Hickman P, Miller D, Hollis KA, Cook S. The relationship between dosing of alosetron and discontinuation patterns reported by patients participating in a follow-up programme. Aliment Pharmacol Ther. 2007 Feb 1;25(3):317-22.
Miller DP, Bennett L, Hollis KA, Tennis P, Cook SF, Andrews E. A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme. Aliment Pharmacol Ther. 2006 Sep 1;24(5):869-78.
Andrews EB, Eaton SC, Hollis KA, Hopkins JS, Ameen VZ, Hamm LR, Mangel AW, Tennis P, Cook SF. Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment Pharmacol Ther. 2005 Nov 10;22:935-42.
Andrews EB, Hollis KA, Miller D, Tennis P, Bennett L, Ameen VZ, Heath A, McSorley D, Cook SF. A patient follow-up survey program for lotronex (Alosetron HCL): accessing compliance with the risk management program. Poster presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux.
Eaton SC, Mangel AW, Hollis KA, Ameen VZ, Hamm LR, Andrews EB, Williams RL, Cook SF. Symptoms of diarrhea-predominant or alternating IBS: an exploratory analysis. Poster presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux.
Eaton SC, Andrews EB, Hollis KA, Hopkins JS, Ameen VZ, Hamm L, Mangel AW, Williams RL, Cook SF. Prevalence and demographics of ibs respondents: results from a large web-based survey. Poster presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux.